key: cord-0860334-poc5aojw authors: Simrén, Joel; Ashton, Nicholas J.; Blennow, Kaj; Zetterberg, Henrik title: Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions date: 2021-02-20 journal: Alzheimers Dement (Amst) DOI: 10.1002/dad2.12145 sha: 56aeab1ae97534e1471a01379f806b2c616c0c1b doc_id: 860334 cord_uid: poc5aojw INTRODUCTION: This study investigated alternative pre‐analytical handling of blood for neurofilament light (NfL) analysis where resources are limited. METHOD: Plasma NfL was measured with single molecule array after alternative blood processing procedures: dried plasma spots (DPS), dried blood spots (DBS), and delayed 48‐hour centrifugation. These were compared to standardized plasma processing (reference standard [RS]). In a discovery cohort (n = 10) and a confirmatory cohort (n = 21), whole blood was obtained from individuals with unknown clinical etiology. In the confirmatory cohort, delayed centrifugation protocol was paired with either 37°C incubation or sample shaking to test the effect of these parameters. RESULTS: Delayed centrifugation (R(2) = 0.991) and DPS (discovery cohort, R(2 )= 0.954; confirmatory cohort, DPS: R(2) = 0.961) methods were strongly associated with the RS. Delayed centrifugation with higher temperatures (R(2) = 0.995) and shaking (R(2) = 0.975) did not affect this association. DPS (P < 0.001) returned concentrations considerably lower than the RS. DISCUSSION: DPS or delayed centrifugation are viable pre‐analytical procedures for the accurate quantification of plasma NfL. There is increasing evidence supporting the value of blood biomarkers in research contexts, clinical evaluation, and pharmaceutical trials of neurological diseases. This is to a large extent owing to the rapid evolution of technological advances of immunoassay-based platforms, such as single molecule array (Simoa). One breakthrough has been the femtomolar quantification of neurofilament light (NfL) in blood, 1 one of and storage of plasma or serum. Several studies have reported the very limited effects of freeze-thaw cycles and plasma storage at room temperature (RT) on NfL stability, [8] [9] [10] but for NfL to be accessible also in remote and less privileged conditions, alternative blood sampling protocols need to be considered. To overcome this issue, quick and inexpensive methods not reliant upon strict cold-chain transport should be developed. Furthermore, methods in which a blood sample could be conceivably obtained in patient/participant homes would increase clinical outreach and participant involvement in therapeutic trials. This would also be of great value to enable research studies being continued during the COVID-19 pandemic. Methods with potential to meet these requirements include dried blood (DBS) 11 or plasma spots (DPS), 12 the latter being simplified recently in the form of Noviplex cards, with builtin technology to separate soluble proteins from the cell fraction of whole blood. These methods have proven feasible to use for the measurement of NfL. 12 Alternatively, one could transport collecting tubes with whole blood and delay sample preparation to the arrival at an advanced laboratory. This would also simplify blood collection at pointof-care. Blood-based biomarkers hold great promise, and reaching distant populations would even further increase their value. Therefore, we aimed to evaluate alternative methods to simplify the pre-analytical procedure of blood NfL measurements in 31 individuals from two cohorts. Fresh blood samples (leftover whole blood from clinical routine analyses) were collected at the Clinical Chemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, as a part of routine evaluation. The discovery cohort used blood samples from n = 10 individuals, whereas n = 21 individuals were included in the confirmatory cohort. The study was conducted in accordance with the Ethics Committee at University of Gothenburg (EPN140811). Because all samples were provided anonymously by laboratory personnel and left over from clinical routine, no informed consent was necessary for this study to be conducted. Blood was collected by venipuncture in EDTA tubes (Vacuette® tube 6 mL, #456243, Greiner Bio-One GmbH, Kremsmuenster, Austria). As reference standard (RS), in both cohorts, blood was centrifuged within 2 hours of collection at 20 • C, spun at 2000 g for 10 minutes and stored at -80 • C pending biochemical analysis. In the dis- Additionally, whole blood was aliquoted into new EDTA tubes, which were then kept at RT for 48 hours before being handled according to standard plasma protocol. In the confirmatory cohort, whole blood was again spotted onto Noviplex DPS cards but not DBS. Instead of storing samples on a lab bench at RT, the aim was to simulate transport in equatorial conditions. Thus, whole blood was stored either at 37 • C for 48 hours, or shaken on a rocker for 3 hours at 300 RPM, and then standing on a lab bench for 45 hours before being handled according to standard plasma protocol. Prior to analysis, DBS cards were collected by cutting with a steril- Noviplex DPS sample in the discovery cohort fell below the limit of detection of the assay. Associations between the RS and alternative sample processing methods were assessed using linear regression models. Wilcoxon signed rank tests were used to compare the absolute concentrations of alternative processing methods against the RS. All statistical analyses were performed in GraphPad Prism version 8.0.0 for Mac (GraphPad Software). Two-sided significance was set at P < 0.05. Strong associations were found for all three alternative sample handling protocols with the RS. Noviplex DPS cards (R 2 = 0.954, P < 0.0001: Figure 1A ) and DBS cards (R 2 = 0.589, P = 0.009, Figure 1B) were slightly less associated than delayed centrifugation at RT, which displayed a near perfect association (R 2 = 0.991, P < 0.0001: Figure 1C ). These results were largely replicated in the confirmatory cohort (Noviplex DPS: R 2 = 0.961, P < 0.0001: Figure 1D ). It was also proven that shaking (R 2 = 0.975, P < 0.0001: Figure 1E ) of the samples or exposure to higher temperature (R 2 = 0.995, P < 0.0001: Figure 1F) did not affect the promising results of delayed centrifugation from the discovery cohort. In both cohorts, Noviplex DPS and DBS cards returned significantly lower concentrations of NfL compared to the RS (DPS: Figure 2A , discovery cohort, P < 0.01; Figure 2D confirmatory cohort, P < 0.0001; DBS: P < 0.05, Figure 2 ). The delayed centrifugation at RT as well as incubation at 37 • C gave slightly higher concentrations of NfL than the RS (P < 0.05, Figure 2C , 2F). No differences were observed for shaking in the confirmatory cohort ( Figure 2E ). In this study, we provide evidence that NfL concentrations remain stable after delaying centrifugation of whole blood. We also corroborate previous results that Noviplex DPS results strongly correlate with RS plasma concentrations, albeit at lower concentrations. 12 First, delayed centrifugation of whole blood while exposing it to shaking did not affect NfL concentrations, while they only slightly increased when whole blood was stored at 37 • C and at RT in the discovery cohort. This highlights the stability of plasma NfL, and enables DBS sampling was first introduced in 1961 as a method to detect phenylketonuria as a part of the newborn screening program, 11 and has since been used in various conditions, such as in the determination of HbA1c concentration 13 and human immunodeficiency virus viral load. 14 Here, we show that concentrations of NfL in DBS cards correlate with the RS, similar to what was found in a prior study. 12 However, the complex matrix of the elute, similar to hemolyzed blood, likely contains proteases, membrane components, and hemoglobin, which could explain the results being inferior to Noviplex DPS and delayed centrifugation methods. Strengths of this study include the availability of whole blood that could be prepared instantly after collection, as well as the comparison of several putative pre-analytical methods in a controlled environment. In a clinical or research scenario, it is desired to measure several analytes implicated in neurological disease, such as tau phosphorylated at amino acid 181 [15] [16] [17] or 217, 18, 19 total tau, 20 glial fibrillary acidic protein, 21 Plasma concentration of the Neurofilament Light Protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study Diagnostic value of plasma neurofilament light: A multicentre validation study. PREPRINT (Version 1) available at Research Square Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease Neurofilaments in progressive multiple sclerosis: a systematic review Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports Serum neurofilament light is sensitive to active cerebral small vessel disease Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial Stability of bloodbased biomarkers of Alzheimer's disease over multiple freeze-thaw cycles Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease Blood screening for phenylketonuria The potential of neurofilaments analysis using dry-blood and plasma spots The use of dried blood spot sampling for the measurement of HbA1c: a cross-sectional study Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease Serum neurofilament light chain for prognosis of outcome after cardiac arrest Plasma glial fibrillary acidic protein in the differential diagnosis of intracerebral hemorrhage Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions